Drug Approval | August 22, 2023
Jiangsu Hengrui Pharmaceuticals gets NMPA approval of oteseconazole Ccapsules
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Oteseconazole Capsules were found to be safe and more effective than fluconazole
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)